<DOC>
	<DOCNO>NCT00408603</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate , safety identify potential biomarkers platinum-resistant ovarian cancer patient treat voreloxin injection give 28-day cycle .</brief_summary>
	<brief_title>Safety Efficacy Clinical Study SNS-595 Patients With Platinum-Resistant Ovarian Cancer</brief_title>
	<detailed_description>Other objective study evaluate Progression-free survival measure CA-125 response rate .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Histologically cytologically document epithelial ovarian cancer , primary peritoneal carcinoma , fallopian tube cancer Completed least one Platinum Based Therapy ( PBT ) regimen ( carboplatin , cisplatin , another organoplatinum compound ) . Evidence platinumresistant disease , relapse/progression within 6 month completion PBT , intolerant PBT ( inability receive PBT due hypersensitivity reaction platinum ) Patients primary platinumresistant disease allow receive one nonplatinum cytotoxic regimen one noncytotoxic regimen management recurrent persistent disease development primary platinumresistance . Measurable disease per GOGRECIST criterion GOG Performance Status 0 1 Radiotherapy , chemotherapy , hormonal , cytokine , target therapy , within 3 week ( nitrosurea mitomycin C within 6 week ) prior anticipate first day treatment . Monoclonal antibody therapy within 4 week prior clinical study entry Unresolved impending bowel obstruction Other active malignancy malignancy within last 12 month except nonmelanoma skin cancer cervical intraepithelial neoplasia Prior radiotherapy 25 % marrow space Requiring hemodialysis peritoneal dialysis Myocardial infarction cerebrovascular accident/transient ischemic attack within 6 month prior anticipate first day treatment Thromboembolic event ( deep vein thrombosis [ DVT ] pulmonary embolus [ PE ] ) within 28 day prior anticipate first day treatment History active CNS metastases Any medical , psychological , social condition would contraindicate patient 's participation clinical study due safety compliance clinical study procedure . Please note : There additional inclusion/exclusion criterion study . Please contact study center additional information determine meet study criterion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>second line treatment</keyword>
	<keyword>platinum resistant</keyword>
	<keyword>ovary</keyword>
	<keyword>ovary</keyword>
	<keyword>cancer</keyword>
	<keyword>epithelial</keyword>
	<keyword>carcinoma</keyword>
	<keyword>tumor</keyword>
</DOC>